Immunocore Holdings Investor Relations Material

Immunocore Holdings plc is a commercial-stage biotechnology company focused on the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune diseases. Utilizing its proprietary T cell receptor (TCR) technology, the company aims to create transformative medicines to address unmet medical needs. Among its notable products is KIMMTRAK, designed for the treatment of patients with unresectable or metastatic uveal melanoma. Immunocore is headquartered in Abingdon, the United Kingdom, and is listed on the NASDAQ stock exchange under the ticker symbol IMCR.